Abstract:Parkinson's disease (PD) is among the most prevalent neurodegenerative disorders, affecting over 10 million people worldwide. The protein encoded by the SNCA gene, alpha‐synuclein (ASYN), is the major component of Lewy body (LB) aggregates, a histopathological hallmark of PD. Mutations and posttranslational modifications (PTMs) in ASYN are known to influence protein aggregation and LB formation, possibly playing a crucial role in PD pathogenesis. In this work, we applied computational methods to characterize the effects of missense mutations and PTMs on the structure and function of ASYN. Missense mutations in ASYN were compiled from the literature/databases and underwent a comprehensive predictive analysis. Phosphorylation and SUMOylation sites of ASYN were retrieved from databases and predicted by algorithms. ConSurf was used to estimate the evolutionary conservation of ASYN amino acids. Molecular dynamics (MD) simulations of ASYN wild‐type and variants A30G, A30P, A53T, and G51D were performed using the GROMACS package. Seventy‐seven missense mutations in ASYN were compiled. Although most mutations were not predicted to affect ASYN stability, aggregation propensity, amyloid formation, and chaperone binding, the analyzed mutations received relatively high rates of deleterious predictions and predominantly occurred at evolutionarily conserved sites within the protein. Moreover, our predictive analyses suggested that the following mutations may be possibly harmful to ASYN and, consequently, potential targets for future investigation: K6N, T22I, K34E, G36R, G36S, V37F, L38P, G41D, and K102E. The MD analyses pointed to remarkable flexibility and essential dynamics alterations at nearly all domains of the studied variants, which could lead to impaired contact between NAC and the C‐terminal domain triggering protein aggregation. These alterations may have functional implications for ASYN and provide important insight into the molecular mechanism of PD, supporting the design of future biomedical research and improvements in existing therapies for the disease.

The αSynuclein half-life conundrum

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Synthesis and Semi-Synthesis of Alpha-Synuclein: Insight into the Chemical Complexity of Synucleinopathies

In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword

Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration

Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease

α-Synuclein in Parkinson's Disease: 12 Years Later

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

In silico analysis of alpha‐synuclein protein variants and posttranslational modifications related to Parkinson's disease

Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification

Initiation and propagation of α-synuclein aggregation in the nervous system

Alpha-Synuclein Aggregation in Parkinson's Disease

Navigating the Neurobiology of Parkinson's: The Impact and Potential of α-Synuclein

Conformational equilibria in monomeric alpha-synuclein at the single molecule level

Changes of α-synuclein After Accumulation

Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified Α-Synuclein.

Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis

α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders